Media Release: Clayton Utz acts for Tattarang on its investment in ASX-listed Emyria Limited

22 Nov 2021

Perth, 22 November 2021: Clayton Utz is acting for Tattarang, one of Australia's largest private investment groups, on its investment in ASX-listed, Emyria Limited (ASX: EMD).  The transaction was announced to the market today.

Perth-based Corporate partner Mark Paganin and special counsel Stephen Neale are leading our team working alongside Tattarang's team, with support from lawyer Hannah Kim. 

Tattarang's $5 million investment into Emyria will take the form of a share placement, under which Tattarang will be issued 20 million shares at an issue price of $0.25 per share and 10 million options.  Following completion of the placement, Tattarang will hold approximately 7.3% of Emyria.

Emyria is focused on accelerating treatment development and improving patient care.  Its treatments target unmet needs and are focused on obtaining approval from major global regulators.

Get in touch

Clayton Utz communications are intended to provide commentary and general information. They should not be relied upon as legal advice. Formal legal advice should be sought in particular transactions or on matters of interest arising from this communication. Persons listed may not be admitted in all States and Territories.